The results of the combined [11C] PIB and [18F] FDG PET patterns data and the clinical diagnosis are used in a multimodal, multitracer andmultivariate analysis approach to demonstrate regional and voxelwise correlations.
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
neurodegeneratieve aandoening/ dementie
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The results of the PET imaging data and the clinical diagnosis are used in a
multimodal, multitracer and multivariate analysis approach to demonstrate
regional and voxelwise correlations between FDG PET and PIB PET. SSM/PCA will
be applied using software
written in-house, based on method of Eidelberg research group (14) with a
univariate and multivariate analyis method. Outcome is measured in so-called
z-scores.
Secondary outcome
The correct differentiation of AD between normal healthy controls (CP) and
frontotemporal dementia
(FTD) and Lewy Body dementia (DLB).
Background summary
Alzheimer*s Disease (AD) is a progressive dementing and neurodegenerative
disorder that is characterized by accumulation of extracellular amyloid plaques
and
intracellular neurofibrillary tangles. Since the development of in vivo
biomarkers,
the pathophysiological process is becoming more important in clinical
diagnosis, as
recommended in the National Institute on Aging -Alzheimer Association (NIA-AA).
PET
biomarkers are Pittsburgh compound-B [11C]PIB, an amyloid marker, showing
increased PIB depositions especialy in the
fronto-temporal region and decreased 18F- fluorodeoxyglucose
(FDG) PET metabolism in the temporo-parietal regions as a marker of downstream
neuronal
degeneration. To explain this discrepancy in localisation between the
pathological pattern of PIB and FDG PET we will use multivariate analysis based
on a Principal Component Analysis (PCA) for combined [18F] FDG PET pattern and
the binding
of [11C] PIB PET in AD. Also we will investigate correct differentiation of AD
between normal
healthy controls (CP), mild cognitive impairement (MCI) and frontotemporal
dementia (FTD) and Lewy Body dementia (DLB).
Study objective
The results of the combined [11C] PIB and [18F] FDG PET patterns data and the
clinical diagnosis are used in a multimodal, multitracer and
multivariate analysis approach to demonstrate regional and voxelwise
correlations.
Study design
All subjects will undergo two PET scans on the same day with a PET protocol
with [11C] PIB
and subsequently [18F] FDG PET. Total duration will be 100 minutes. A follow up
neuropsychological assessment will be done, to detect progression of dementia.
In a
subgroup of patients follow up investigation will be done because of clinical
purposes or by
future ability of new and potential more specific diagnostic PET markers.
PET scans will be performed using a Siemens Biograph mCT integrated PET/CT
scanner in
3-dimensional acquisition mode. The properties of this scanner have been
reported
elsewhere (32). A low dose CT scan will be acquired before the PET scan to
correct the PET
data for attenuation. A [11C] PIB PET and [18F] FDG PET will be performed on
the same day.
Intervention
All subjects will undergo two PET scans on the same day with a PET protocol
with [11C] PIB
and subsequently [18F] FDG PET. Total duration will be 100 minutes.
Study burden and risks
This study entails minimum risk to the participant. The subjects will visit
the Nuclear Medicine department for a combined PET scan with a total duration of
approximate 100 minutes. The investigation can contribute for the clinical
diagnosis of the
subject. Also the study will contribute valuable scientific knowledge to the
fields of dementia
and Nucleair Medicine.
Hanzeplein 1
Groningen 9713GZ
NL
Hanzeplein 1
Groningen 9713GZ
NL
Listed location countries
Age
Inclusion criteria
Age from 50 - 80 yr
Willingness to cooperate and sign written informed consent
Exclusion criteria
- History of major psychiatric illness
- Medications which may affect outcome
- Cerebrovascular disease with cortical infarcts or a Fazekas- score of 2 or higher
- Pregnancy
- Mentally incompetent to understand full consequence of a written informed consent
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL50217.042.15 |